This may affect your ability to complete your registration.
SCHOOL OF MEDICINE - SoMCC
INDUSTRY INSIGHTS WITH INVITAE:
Genomic Medicine: The Future is Now
Wednesday, February 13th, 12:00-1:30pm
School of Medicine, Li Ka Shing Center for Learning & Knowledge (LKSC) - Room 130
Lunch will be served.
Jill M. Hagenkord, MD, FCAP
Chief Medical Officer & Senior Vice President, InVitae
School of Medicine Career Center
Overview: Recent technological advances in nucleic acid sequencing have made it possible to inexpensively test hundreds or thousands of analytes in a single clinical assay (genomic pathology) rather than the one-analyte-at-a-time approach used historically. In turn, this is catalyzing a paradigm shift in medicine from reactive and opaque to predictive, preventive, personalized, participatory, and philanthropic (genomic medicine). Dozens of clinical laboratories across the country are now offering next generation sequencing assays for germline and cancer application. Dr. Hagenkord will provide an overview of InVitae, a privately held company pursuing the goal of bringing comprehensive genetic information into routine medical practice to improve the quality of healthcare worldwide. InVitae is developing the capabilities to aggregate the world’s genetic tests into a single assay with better quality, faster turnaround time, and a lower price than most single-gene assays today. This disruptive technology has far reaching implications for medical care. Time will also be allotted to discussing industry career options for medical and life science trainees.
About the Speaker: Dr. Hagenkord is a genomic pathologist with board certification in pathology and molecular genetic pathology. Prior to joining InVitae, Jill served as Chief Medical Officer and Senior Vice President at Complete Genomics, Inc. Her other prior experiences include founder and Chief Medical Officer for iKaryos Diagnostics, Associate Professor of Pathology at Creighton University School of Medicine, Director of Molecular Pathology and Clinical Genomics at Creighton Medical Laboratories, and pathologist at Deltagen, Inc. Dr. Hagenkord received her MD from Stanford University School of Medicine in 1999, did her residency training in pathology at the University of California at San Francisco and the University of Iowa, and completed fellowships in Pathology/Oncology Informatics and Molecular Genetic Pathology at the University of Pittsburgh Medical Center.
Questions? Email Carla Vaccarezza at email@example.com.